TransMedics Group (NASDAQ:TMDX) Hits New 12-Month Low on Disappointing Earnings

Key Points

• Shares plunged to a new 52-week low, falling about 20.9% intraday after TransMedics reported Q1 EPS of $0.30, well below the consensus of ~$0.62 and down from $0.70 a year earlier.
• Revenue grew 21.2% year‑over‑year to $173.93M but slightly missed estimates (~$174.5M); management provided FY‑2026 revenue guidance of $727M–$757M, a wide range that leaves near‑term pacing uncertain.
• Insiders (including the CFO) have been selling shares and analyst views are mixed — the consensus is a "Moderate Buy" with an average price target of $148.78, substantially above the current ~ $75 share price.

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report)'s stock price reached a new 52-week low during mid-day trading on Wednesday following a weaker than expected earnings announcement. The stock traded as low as $72.12 and last traded at $75.1480, with a volume of 1538455 shares changing hands. The stock had previously closed at $94.93.

The company reported $0.30 EPS for the quarter, missing analysts' consensus estimates of $0.62 by ($0.32). TransMedics Group had a net margin of 31.43% and a return on equity of 30.17%. The company had revenue of $173.93 million during the quarter, compared to analyst estimates of $174.48 million. During the same period in the previous year, the company earned $0.70 EPS. The company's quarterly revenue was up 21.2% compared to the same quarter last year.

Key Headlines Impacting TransMedics Group

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Q1 revenue grew 21.2% year‑over‑year to $173.9M, indicating continued demand expansion for TransMedics’ organ‑preservation systems and consumables. TransMedics Reports First Quarter 2026 Financial Results
• Positive Sentiment: Profitability remains strong on reported metrics: net margin ~31.4% and ROE ~30.2%, which signal healthy unit economics and operational leverage as revenue scales. MarketBeat Q1 Summary & Materials
• Neutral Sentiment: Management issued FY-2026 revenue guidance of $727M–$757M (consensus ~$739M). The range includes the Street estimate but is wide, leaving room for investor interpretation on pacing and margin assumptions. Guidance Update (company release/slides)
• Neutral Sentiment: Company provided supporting materials (press release, slide deck, and conference call transcript) that investors can review for detail on regional trends, disposable attach rates, and cadence of system placements. Earnings Call Transcript
• Negative Sentiment: Q1 EPS missed materially: $0.30 vs. consensus ~$0.62, and down from $0.70 a year ago — this earnings miss drove near‑term investor disappointment. Zacks: Q1 Earnings and Revenues Miss Estimates
• Negative Sentiment: Revenue was a slight miss versus consensus ($173.93M vs. ~$174.5M), reinforcing the EPS shortfall and prompting questions about near‑term margin or timing issues. Zacks: What Key Metrics Have to Say

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. TD Cowen reaffirmed a "buy" rating on shares of TransMedics Group in a research report on Monday, March 16th. Wall Street Zen cut shares of TransMedics Group from a "buy" rating to a "hold" rating in a research report on Saturday, February 28th. Stifel Nicolaus increased their price target on shares of TransMedics Group from $115.00 to $130.00 and gave the stock a "hold" rating in a research report on Monday, March 9th. Oppenheimer cut shares of TransMedics Group from an "outperform" rating to a "market perform" rating in a research report on Wednesday. Finally, Needham & Company LLC reduced their price target on shares of TransMedics Group from $174.00 to $142.00 and set a "buy" rating on the stock in a research report on Wednesday. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $148.78.

Insider Buying and Selling at TransMedics Group

In other news, insider Nicholas Corcoran sold 2,966 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $139.12, for a total transaction of $412,629.92. Following the sale, the insider owned 29,831 shares of the company's stock, valued at approximately $4,150,088.72. This represents a 9.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Gerardo Hernandez sold 7,236 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $147.21, for a total transaction of $1,065,211.56. Following the sale, the chief financial officer directly owned 14,689 shares in the company, valued at $2,162,367.69. This represents a 33.00% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 16,205 shares of company stock valued at $2,353,002. Corporate insiders own 6.90% of the company's stock.

Institutional Trading of TransMedics Group

Hedge funds have recently added to or reduced their stakes in the company. Whittier Trust Co. of Nevada Inc. raised its holdings in TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company's stock valued at $26,000 after acquiring an additional 206 shares in the last quarter. Salomon & Ludwin LLC acquired a new stake in TransMedics Group in the third quarter valued at approximately $28,000. Harvest Fund Management Co. Ltd acquired a new stake in TransMedics Group in the third quarter valued at approximately $29,000. Allworth Financial LP raised its holdings in TransMedics Group by 74.3% in the third quarter. Allworth Financial LP now owns 265 shares of the company's stock valued at $30,000 after acquiring an additional 113 shares in the last quarter. Finally, Optiver Holding B.V. raised its holdings in TransMedics Group by 248.1% in the third quarter. Optiver Holding B.V. now owns 268 shares of the company's stock valued at $30,000 after acquiring an additional 191 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Trading Down 20.9%

The company's fifty day moving average is $116.57 and its two-hundred day moving average is $125.96. The stock has a market cap of $2.59 billion, a price-to-earnings ratio of 15.31 and a beta of 2.07. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.